Bisoprolol

Bisoprolol

SCHEMBL20960

CC(C)NCC(O)COc1ccc(COCCOC(C)C)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRB1

The experimentally established mechanism targets of Bisoprolol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB1 known ✓ P08588 5/20 1.00
ADRB2 P07550 4/20 1.00
ADRB3 P13945 2/20 1.00
LMNA P02545 3/20 0.83
NFKB1 P19838 2/20 0.83
MEN1 O00255 1/20 0.83
THRB P10828 1/20 0.83
ALOX12 P18054 1/20 0.83
APEX1 P27695 1/20 0.83
MAPK1 P28482 1/20 0.83
KMT2A Q03164 1/20 0.83
PTGS1 P23219 1/20 0.63
SLC6A2 P23975 1/20 0.63
CYP2D6 P10635 3/20 0.62
ADRA1A P35348 2/20 0.62
NR3C1 P04150 1/20 0.62
CYP2J2 P51589 1/20 0.62
PDE4D Q08499 1/20 0.62
MAPT P10636 1/20 0.60
TDP1 Q9NUW8 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bisoprolol SCHEMBL20961 1.00 ADRB1 (1.00) ADRB1ADRB2ADRB3LMNANFKB1
Bisoprolol SCHEMBL233810 1.00 ADRB1 (1.00) ADRB1ADRB2ADRB3LMNANFKB1
Bisoprolol SCHEMBL6510329 1.00 ADRB1 (1.00) ADRB1ADRB2ADRB3LMNANFKB1
Bisoprolol SCHEMBL16821829 0.99 ADRB1 (0.98) ADRB1ADRB2ADRB3LMNANFKB1
Bisoprolol SCHEMBL16821831 0.99 ADRB1 (0.98) ADRB1ADRB2ADRB3LMNANFKB1
Bisoprolol SCHEMBL4269272 0.99 ADRB1 (0.98) ADRB1ADRB2ADRB3LMNANFKB1
Bisoprolol SCHEMBL3137111 0.99 ADRB2 (0.98) ADRB1ADRB2ADRB3LMNANFKB1
Bisoprolol SCHEMBL3137123 0.99 ADRB2 (0.98) ADRB1ADRB2ADRB3LMNANFKB1
Bisoprolol SCHEMBL14343724 0.94 ADRB2 (0.89) ADRB1ADRB2ADRB3LMNANFKB1
Bisoprolol SCHEMBL28880254 0.94 ADRB2 (0.89) ADRB1ADRB2ADRB3LMNANFKB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 22415 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3607938-B1 PHARMACEUTICAL COMPOSITION SOVIC BRKICIC LJILJANA (HR) 2026-05-27 EP claimed
WO-2026103722-A1 COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF COAGULATION FACTOR XI (FXI) SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD. (CN) 2026-05-21 WO claimed
WO-2026103833-A1 PHARMACEUTICAL COMPOSITION OF ARNI AND BISOPROLOL OR SALT THEREOF, AND USE THEREOF 深圳信立泰药业股份有限公司 2026-05-21 WO claimed
CN-224227077-U Immobilized enzyme reactor for bisoprolol synthesis 浙江希尔化工股份有限公司 2026-05-12 CN claimed
EP-4731194-A1 MATERIALS AND METHODS FOR MITIGATING THE PRESENCE OF NITROSAMINES IN PACKAGING USING AN ACTIVE AGENT CSP Technologies, Inc. (US) 2026-04-29 EP claimed
EP-4727545-A2 COMBINATION TREATMENTS FOR DEPRESSION AND OTHER DISORDERS Neurawell Therapeutics (US) 2026-04-22 EP claimed
EP-4722714-A1 SIMULTANEOUS ANALYSIS OF FOOD-BORNE DOPING SUBSTANCES USING LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY (VFD: VACCINE FOR FOODBORNE DOPING) Korea Institute of Science and Technology (KR) 2026-04-08 EP claimed
US-20260076953-A1 METHODS OF DIAGNOSING AND TREATING ADHD IN BIOMARKER POSITIVE SUBJECTS THE CHILDREN'S HOSPITAL OF PHILADELPHIA (US) 2026-03-19 US claimed
EP-4709379-A1 NMDAR ANTAGONIST FOR THE TREATMENT OF INFLAMMATORY DISEASES IN PATIENTS WITH DEPRESSION COMORBIDITY THE SARAH HERZOG MEMORIAL HOSPITAL-EZRATH NASHIM (IL) 2026-03-18 EP claimed
EP-4694856-A1 CALENDAR MEDICATION BLISTER PACK, METHOD OF USING THEREOF AND ELECTRONIC SYSTEM OF MANAGEMENT OF INTERACTION WITH CALENDAR MEDICATION BLISTER PACK Mili Healthcare Trade Fzco (AE) 2026-02-18 EP claimed
EP-0209897-A2 Peptide enzyme inhibitors MERCK & CO. INC. (US) 1987-01-28 EP claimed
EP-0068160-B1 USE OF 1-(P-ISOPROPOXYETHOXYMETHYL-PHENOXY)-3-ISOPROPYLAMINOPROPAN-2-OL FOR THE PREPARATION OF A MEDICAMENT FOR THE REDUCTION OF INTERNAL PRESSURE IN THE EYE MERCK PATENT GmbH (DE) 1986-10-29 EP claimed
EP-0163237-A2 Di- and tri-peptidal renin inhibitors MERCK & CO. INC. (US) 1985-12-04 EP claimed
EP-0157409-A2 Renin inhibitors containing 2-substituted statine MERCK & CO. INC. (US) 1985-10-09 EP claimed
EP-0156318-A2 C-terminal amide cyclic renin inhibitors containing peptide isosteres MERCK & CO. INC. (US) 1985-10-02 EP claimed
EP-0156322-A2 Renin inhibitors containing peptide isosteres MERCK & CO. INC. (US) 1985-10-02 EP claimed
US-4522829-A 1-(p-2-Isopropoxyethoxymethyl-phenoxy)-3-isopropylamino-propan-2-ol for decreasing the intra-ocular pressure and an ophthalmic preparation thereof MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1985-06-11 US claimed
EP-0129189-A2 Renin inhibitors containing a C-terminal amide cycle and compositions and combinations containing the same MERCK & CO. INC. (US) 1984-12-27 EP claimed
EP-0068160-A1 Use of 1-(p-Isopropoxyethoxymethyl-phenoxy)-3-isopropylaminopropan-2-ol for the preparation of a medicament for the reduction of internal pressure in the eye MERCK PATENT GmbH (DE) 1983-01-05 EP claimed
US-4258062-A ISOPRENALINE ANTAGONISTS EFFECTING HEART RATE AND BLOOD PRESSURE MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 1981-03-24 US claimed